Loading...
Publication
Efeito do tratamento cirúrgico da obesidade nos níveis de FGF-21
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 624.81 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
O fator de crescimento de fibroblasto 21 (FGF-21) tem sido descrito como tendo efeitos metabólicos benéficos. Acredita-se que estimula a captação de glicose e a lipólise no tecido adiposo, apresentando efeitos anti-inflamatório, anti-diabético e hipolipidémico. Porém, alguns estudos têm sugerido que a obesidade está relacionada com um estado de resistência ao FGF-21, estando os níveis desta proteína aumentados em indivíduos com obesidade ou excesso de peso. O objetivo da presente dissertação é realizar uma revisão da literatura acerca das alterações dos níveis de FGF-21 em indivíduos com obesidade submetidos a cirurgia bariátrica. Para isso, foram feitas pesquisas em três bases de dados: PubMed, Web of Science e Scopus, para artigos publicados entre 2020 e 2024. Da pesquisa, foram incluídos 9 artigos diferentes que geraram 13 séries de dados, com um total de 543 participantes. A média de idades variou entre 36.6 ± 12.8 anos e 51.8 ± 1.8 anos e a média do IMC pré-cirúrgico variou entre 31.63 ± 4.62 e 50.2 ± 9.3 kg/m2. As consultas de acompanhamento pós-cirúrgico ocorreram no mínimo 1 mês e no máximo 24 meses após a cirurgia bariátrica. A cirurgia mais comum foi Roux-en-Y gastric bypass, seguida pela Sleeve gastrectomy. No geral, 9 das 13 séries de dados observaram alterações estatisticamente significativas em algum dos meses estudados. Também, a partir do mês 18, nenhuma das séries de dados apresentou alterações estatisticamente significativas, ou seja, apenas se observaram alterações significativas até aos 12 meses pós-cirurgia bariátrica. Verificou-se que, aparentemente, os níveis de FGF-21 diminuem ao 12º mês pós-cirurgia bariátrica, porém, mais estudos são necessários sobre este tema e com mais meses de acompanhamento para um melhor entendimento das variações dos níveis de FGF-21 ao longo dos meses que se seguem à cirurgia bariátrica.
effects. It is believed to stimulate glucose uptake and lipolysis in adipose tissue, presenting anti-inflammatory, anti-diabetic and hypolipidemic effects. However, some studies have suggested that obesity is related to a state of resistance to FGF-21, with levels of this protein being increased in obese or overweight individuals. The objective of this dissertation is to review the literature on changes in FGF-21 levels in obese individuals undergoing bariatric surgery. For this, searches were carried out in three databases: PubMed, Web of Science and Scopus, for articles published between 2020 and 2024. From the search, 9 different articles were included, generating 13 data series, with a total of 543 participants. The mean age ranged between 36.6 ± 12.8 years and 51.8 ± 1.8 years and the mean pre-surgery BMI ranged between 31.63 ± 4.62 and 50.2 ± 9.3 kg/m2. Post-surgical follow-up appointments occurred at least 1 month and at most 24 months after bariatric surgery. The most common surgery was Roux-en-Y gastric bypass, followed by sleeve gastrectomy. Overall, 9 of the 13 data series observed statistically significant changes in any of the follow-up months. Also, from month 18 onwards, none of the data series showed statistically significant changes, that is, significant changes were only observed up to 12 months post-bariatric surgery. Apparently, at month 12 post-bariatric surgery, FGF-21 levels are decreased compared to pre-surgical levels, however, more studies are needed on this topic and with more follow-up time-points for a better understanding of variations in FGF-21 levels over the months following bariatric surgery.
effects. It is believed to stimulate glucose uptake and lipolysis in adipose tissue, presenting anti-inflammatory, anti-diabetic and hypolipidemic effects. However, some studies have suggested that obesity is related to a state of resistance to FGF-21, with levels of this protein being increased in obese or overweight individuals. The objective of this dissertation is to review the literature on changes in FGF-21 levels in obese individuals undergoing bariatric surgery. For this, searches were carried out in three databases: PubMed, Web of Science and Scopus, for articles published between 2020 and 2024. From the search, 9 different articles were included, generating 13 data series, with a total of 543 participants. The mean age ranged between 36.6 ± 12.8 years and 51.8 ± 1.8 years and the mean pre-surgery BMI ranged between 31.63 ± 4.62 and 50.2 ± 9.3 kg/m2. Post-surgical follow-up appointments occurred at least 1 month and at most 24 months after bariatric surgery. The most common surgery was Roux-en-Y gastric bypass, followed by sleeve gastrectomy. Overall, 9 of the 13 data series observed statistically significant changes in any of the follow-up months. Also, from month 18 onwards, none of the data series showed statistically significant changes, that is, significant changes were only observed up to 12 months post-bariatric surgery. Apparently, at month 12 post-bariatric surgery, FGF-21 levels are decreased compared to pre-surgical levels, however, more studies are needed on this topic and with more follow-up time-points for a better understanding of variations in FGF-21 levels over the months following bariatric surgery.
Description
Keywords
Fator de crescimento de fibroblasto 21 Cirurgia bariátrica Obesidade